TuHURA Biosciences vs Phio Pharmaceuticals
HURA and PHIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HURA and PHIO compare
TuHURA Biosciences is the larger company, worth 11 times as much as Phio Pharmaceuticals ($89.2M against $8.3M).
Phio Pharmaceuticals scores higher on the StockData Score (5 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HURA | PHIO |
|---|---|---|
| Size and price | ||
| Market cap | $89.2M | $8.3M |
| Share price | $1.40 | $0.717 |
| Change, 1 year | −31.7% | −44.8% |
| Change, 5 years | −99.9% | −99.5% |
| Beta (5Y) | 1.98 | −0.31 |
| Employees | 22 | 6 |
| StockData Score | ||
| Total score | 0 | 5 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 4.8× | 0.7× (better) |
| FCF yield | −33.5% (better) | −147% |
| Profitability | ||
| Return on equity | −161% | −114% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.18 | – |
| Altman Z-score | −3.21 (better) | −16.15 |
| Piotroski F-score | 2 | – |
| Dividends and buybacks | ||
| Buyback yield | −22.6% | – |
| Shareholder yield | −22.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 14.1% | 5.6% |
| Held by insiders | 4.9% | 10.9% |
| Insider net buying, 12 months | – | $135K |
| Short interest, % of float | 10.2% | 0.83% |
Go deeper
- HURA stock overview
- HURA income statement
- HURA valuation and score
- PHIO stock overview
- PHIO income statement
- PHIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.